Randomised trials of secondary prevention programmes in coronary heart disease: systematic reviewBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7319.957 (Published 27 October 2001) Cite this as: BMJ 2001;323:957
- Finlay A McAlister, assistant professora (, )
- Fiona M E Lawson, assistant clinical professorb,
- Koon K Teo, professord,
- Paul W Armstrong, professorc
- a Division of General Internal Medicine, 2E3.24 WMC, University of Alberta Hospital, 8440 112 Street, Edmonton, AL, Canada T6G 2R7
- b Division of Geriatric Medicine, University of Alberta, Edmonton, AL, Canada T6G 2R7
- c Division of Cardiology, University of Alberta
- d Division of Cardiology, McMaster University, Hamilton, ON, Canada L8S 4l8
- Correspondence to: F McAlister
- Accepted 29 August 2001
Objective: To determine whether multidisciplinary disease management programmes for patients with coronary heart disease improve processes of care and reduce morbidity and mortality.
Data sources: Randomised clinical trials of disease management programmes in patients with coronary heart disease were identified by searching Medline 1966-2000, Embase 1980-99, CINAHL 1982-99, SIGLE 1980-99, the Cochrane controlled trial register, the Cochrane effective practice and organisation of care study register, and bibliographies of published studies.
Data extraction: Studies were selected and data were extracted independently by two investigators, and summary risk ratios were calculated by using both the random effects model and the fixed effects model.
Data synthesis: A total of 12 trials (9803 patients with coronary heart disease) were identified. Disease management programmes had positive impacts on processes of care. Patients randomised to these programmes were more likely to be prescribed efficacious drugs (risk ratio 2.14 (95% confidence interval 1.92 to 2.38) for lipid lowering drugs, 1.19 (1.07 to 1.32) for β blockers, and 1.07 (1.03 to 1.11) for antiplatelet agents). Five out of seven trials evaluating risk factor profiles showed significantly greater improvements with these programmes in comparison with usual care (with effect sizes in the moderate range). Summary risk ratios were 0.91 (0.79 to 1.04) for all cause mortality, 0.94 (0.80 to 1.10) for recurrent myocardial infarction, and 0.84 (0.76 to 0.94) for admission to hospital. Five of the eight trials evaluating quality of life or functional status reported better outcomes in the intervention arms. Only three of these trials reported the costs of the intervention—the interventions were cost saving in two cases.
Conclusions: Disease management programmes improve processes of care, reduce admissions to hospital, and enhance quality of life or functional status in patients with coronary heart disease. The programmes' impact on survival and recurrent infarctions, their cost effectiveness, and the optimal mix of components remain uncertain.
What is already known on this topic
What is already known on this topic Evidence based cardiac rehabilitation programmes of varying intensity improve morbidity and mortality in survivors of myocardial infarction
Patients with coronary heart disease are increasingly referred to multidisciplinary clinics that use disease management approaches
What this study adds
What this study adds Disease management approaches have a positive impact on processes of care (prescription of proved efficacious drugs and cardiovascular risk profiles of patients)
Most of the trials reported that quality of life or functional status was better in patients treated with disease management rather than usual care The optimal mix of components and the cost effectiveness of these programmes is still uncertain
Coronary heart disease is already the major cause of illness and death in Western countries. The size of this epidemic is likely to increase—populations are ageing, and advances in treatment lead to an increasing number of survivors of myocardial infarction.1 Despite many interventions that have been proved to reduce recurrence of myocardial infarction, audits of practice consistently reveal suboptimal control of cardiovascular risk factors and underuse of antiplatelet agents, β blockers, and lipid lowering drugs in patients with coronary heart disease.2
Disease management programmes are increasingly advocated as a means of improving management of and outcomes for patients with coronary heart disease.3–5 Disease management has been defined as “a combination of patient education, provider use of practice guidelines, appropriate consultation, and supplies of drugs and ancillary services.”3 Although the specific elements of these programmes vary across different settings and disease states, great enthusiasm exists for coronary heart disease management programmes that use multidisciplinary teams and specialised clinics dedicated to the prevention of death or of recurrent myocardial infarction.4
Despite this enthusiasm the effectiveness of these programmes in reducing morbidity and mortality is largely unknown. Many reviews have shown that cardiac rehabilitation programmes improve outcomes in survivors of myocardial infarction,6–8 but these conclusions are based largely on eight trials that tested exercise programmes of varying intensity. Only two of the trials included in these reviews evaluated disease management approaches, and neither of these trials found a benefit from the intervention. Most subsequent studies of multidisciplinary disease management programmes have been uncontrolled before-after case series, and the results of the few randomised trials that have been done are far from conclusive owing to inadequate power. In the absence of a conclusive trial, the data should be examined in a systematic way in an attempt to draw valid conclusions. We thus performed a rigorous systematic review of randomised trials to determine whether multidisciplinary disease management programmes improve processes of care and reduce morbidity and mortality in patients with established coronary heart disease.
Searching for relevant studies
We searched electronic databases (Medline 1966-2000, Embase 1980-99, CINAHL 1982-99, SIGLE 1980-99, the Cochrane controlled trial register, and the Cochrane effective practice and organisation of care study register) for randomised trials in humans; no language restrictions were applied. We used the following textword terms and MeSH headings: case management (exp), comprehensive health care (exp), disease management (exp), health services research (exp), home care services (exp), clinical protocols (exp), patient care planning (exp), quality of health care (exp), rehabilitation, nurse led clinics, special clinics, and myocardial ischemia (exp). To identify any studies missed by the literature searches, we hand searched the bibliographies of all identified studies and contacted experts on the subject.
Selection of studies and abstraction of data
Two of the investigators (FM and FL) independently reviewed the titles and abstracts of all citations to identify any studies reporting the impact of disease management programmes on death, myocardial infarction, or rates of admission to hospital in patients with coronary heart disease (clinically manifest as angina, myocardial infarction, or coronary revascularisation). Both investigators used pre-standardised data abstraction forms to review the full texts of all potentially relevant articles. Any discrepancies were resolved by consensus. Outcomes were assigned according to the intention to treat principle. We contacted original investigators where necessary to clarify the published data.
We excluded studies if they were not randomised, were primary prevention studies, evaluated single modality interventions (such as exercise programmes or telephone follow up), tested inpatient interventions, or enrolled fewer than 50 participants. We included studies in which patients with multiple diseases were enrolled if the outcomes for patients with coronary heart disease were reported separately or if these patients comprised at least half of the study participants.
We used the Meta-Analyst 0.998 software (J Lau, New England Medical Center, Boston, MA) to perform analyses. As the primary outcomes were relatively common, we calculated risk ratios and used Cochran's Q test to assess heterogeneity in each outcome of interest. We combined studies by using both the DerSimonian and Laird random effects model and the Mantel-Haenszel-Peto fixed effects model; as these models gave similar results for all analyses, we report only the fixed effects results here. To standardise the reporting of results for non-dichotomous outcomes (such as change in cholesterol concentrations, blood pressure, or scores for quality of life or functional status), we used the effect size technique described by Kazis et al.9 We calculated the effect size by dividing the absolute difference between intervention and control arms by the standard deviation in the control arms. By convention, effect sizes <0.20 are considered trivially small, 0.50 is moderate, and >0.80 is large. We conducted sensitivity analyses, defined in advance, to look at the effects on the summary risk ratios of quality of study, duration of intervention, length of follow up, year of study completion, and elements of the disease management programme.
Study selection and evaluation
Of the 1562 citations originally identified in our search, we retrieved 72 that seemed potentially relevant. We excluded 55 of these studies after detailed evaluation: 16 were not randomised, 13 were primary prevention studies, eight did not report the primary outcomes, eight evaluated interventions that were not comprehensive disease management systems (such as exercise therapy alone), five did not report the outcomes for patients with coronary heart disease separately or included <50% patients with coronary heart disease, two tested an inpatient based intervention, two enrolled fewer than 50 patients, and one had flawed methods (patients excluded after randomisation). (A full list of excluded studies is available from FM on request.) Our search retrieved 10 trials not included in previous systematic reviews.
Disagreement among the reviewers (FM and FL) regarding eligibility of the studies occurred on four occasions, for a κ value of 0.85. All disagreements were resolved by consensus.
Of the randomised trials eligible for inclusion, three were reported in more than one publication. One trial reported different end points in two separate publications. 10 11 One trial reported the outcomes for all patients enrolled (only 45% of whom had heart disease) and, in a separate publication, provided details of event rates in the subgroup of patients with heart disease. 12 13 The World Health Organization trial included 24 collaborating centres, but the original investigators excluded seven sites because of poor follow up of participants and four sites because of significant differences at baseline between the intervention and control arms.14 We included the three year outcome data from the remaining 13 sites as one trial for the purposes of this analysis, an approach validated by the non-significant tests for statistical heterogeneity for all cause mortality (Q=15.7, 11 df, P=0.16) and myocardial infarction (Q=15.9, 11 df, P=0.15) and the fact that the summary risk ratios for both end points were identical under the random and fixed effects models. Although the two Finnish centres in the WHO trial published their results separately (and for multiple periods of follow up), we included only their three year outcome data with the other 11 WHO sites for consistency of data presentation.15–17
Table 1 presents summary data from the 12 randomised trials eligible for this systematic review. In all of the trials, patients randomised to the control groups received usual care (this was generally undefined).
Quantitative data synthesis
Reinfarction rate—None of the seven trials reporting this end point detected a significant difference between patients in intervention and control arms (fig 1), and the summary risk ratio for all 7480 patients was 0.94 (95% confidence interval 0.80 to 1.10).
All cause mortality—Only one out of 10 trials reported a significant survival benefit with the intervention (fig 2). The summary risk ratio of 0.91 (0.79 to 1.04) for all 10 trials (9718 patients) confirms that these interventions have not been shown to improve survival.
Rate of admission to hospital—Although only two 10 19 of the six trials reporting admission rates 10 13 19 23 25 26 found a significant difference, the summary risk ratio of 0.84 (0.76 to 0.94) is consistent with a beneficial impact of the interventions. Of the four trials that evaluated length of stay, two showed shorter lengths of stay or a reduced total of days in hospital in the intervention group. 13 26 Furthermore, one trial reported that significantly fewer patients in the intervention arms had multiple readmissions.13 There was insufficient detail in these studies to permit analysis by type of admission (for example, cardiac v non-cardiac).
Sensitivity analyses—Year of study completion, duration of intervention, and length of follow up had no effect on the observed results (data not shown). Because of the small number of trials and the poor reporting of the specific elements of the intervention in many of the trials, analyses by different components of the multidisciplinary interventions failed to detect any one component that was statistically beneficial, although there was a trend towards greater survival benefits in those programmes that included structured exercise (risk ratio 0.87 (0.71 to 1.05) v 0.94 (0.78 to 1.13)).
Processes of care—Seven trials tested the impact of the disease management programmes on cardiovascular risk factors; five showed significantly greater improvements in patients randomised to the interventions, although the effect sizes were generally small to moderate (table 2). Of the seven trials that assessed the use of drugs proved to be efficacious, all but two showed significantly increased prescription of at least one of these treatments in the intervention group. Pooled data showed that patients in the intervention arm were more likely to be prescribed these treatments, with risk ratios of 2.14 (1.92 to 2.38) for lipid lowering drugs, 1.19 (1.07 to 1.32) for β blockers, and 1.07 (1.03 to 1.11) for antiplatelet agents. The increases in prescription of β blockers and antiplatelet agents are noteworthy, as these trials tested interventions designed largely to look at lipid lowering in patients with coronary heart disease.
Other end points—Five of the eight trials evaluating quality of life or functional status showed better scores in the intervention arms, although these were generally small and achieved significance in only three studies (table 2). Only three of these trials described the costs of the intervention. 12 20 26 Two reported that their intervention was cost saving, 12 26 but none performed formal cost effectiveness analyses.
The weight of the evidence from randomised controlled trials shows that comprehensive disease management programmes have a positive impact on processes of care (risk factor profiles, prescription of proved efficacious drugs) that are closely linked to subsequent morbidity and mortality in patients with coronary heart disease.28 Although these trials failed to document any convincing survival benefit or reduction in recurrent myocardial infarctions, there was a significant reduction in admissions to hospital and a trend towards improved symptom scores, exercise tolerance, or quality of life with these programmes.
Lack of survival benefit
Previously published systematic reviews of cardiac rehabilitation in survivors of myocardial infarction have shown survival benefits in the order of 20-24%.6–8 However, most of the trials included in those overviews evaluated interventions that were primarily based on exercise (and thus not included in our overview).6–8 As activity levels are inversely proportional to cardiovascular mortality, and exercise training confers substantial physiological and clinical benefits,29 it is not surprising that those trials found greater treatment effects than did trials evaluating multidisciplinary interventions that were not primarily exercise based. Although too few trials in this overview included structured exercise as part of the intervention to show a clearly beneficial treatment effect with this modality, a trend towards greater survival benefit was seen in programmes that included this element.
Why did these trials (including almost 10 000 participants) not show a significant survival benefit? Firstly, these trials may have been too short (median follow up was 12 months) to show a clear impact on mortality. Secondly, the patients included in these studies were at sufficiently low risk that the likelihood of detecting a beneficial effect was remote—the event rates in the control groups in these trials were substantially lower than in other trials enrolling patients with clinically overt coronary heart disease.30 Thirdly, the incremental benefit of disease management over usual care may be very small in the settings in which the trials were carried out (where management in the “usual care” arm may be close to optimal already). Indeed, disease management programmes are likely to be most beneficial in those settings where usual care is suboptimal. Finally, labelling patients as having one disease for a management programme may have led to suboptimal care for their comorbid conditions and, as a result, to no real difference in all cause mortality.31 Nevertheless, we believe that the clear improvements in risk factor profiles and prescription of lipid lowering drugs, β blockers, and antiplatelet agents in patients exposed to these interventions will translate into clinically important reductions in recurrent myocardial infarctions and death.
Limitations of the study
As with all systematic reviews, this study has several potential limitations. The most obvious (the relatively small sample size, the lack of double blind studies, and our inability to identify unpublished studies) arise from the primary data. As these limitations tend to result in overestimation of any treatment effects,32 these limitations in fact strengthen our conclusions about the lack of convincing evidence that coronary heart disease management programmes reduce total mortality or recurrent myocardial infarctions. On the other hand, our interpretation of these trials and the generalisability of the programmes described is hampered by the imprecise descriptions of the interventions and the lack of data to determine the incremental benefits of the various components of each intervention.
Although some people may criticise our choice of primary end points as being too broad to detect differences in “cardiac” morbidity and mortality, we believe that it is most appropriate to look at all cause mortality or admission to hospital, as interventions to reduce use of resources in one area can have unanticipated effects in another. Finally, owing to the paucity of data, we are unable to make a definitive comment on the cost effectiveness and economic impact of the programmes tested in these trials.
Although the interventions that were offered varied substantially and the studies often enrolled highly selected populations, multidisciplinary disease management programmes (particularly those that include a structured exercise component) for secondary prevention in patients with coronary heart disease do seem to have a beneficial impact.
Several questions remain to be answered. In particular, the optimal mix of interventions, their frequency and duration, and their cost effectiveness are still unclear. Furthermore, the lack of convincing evidence of any survival benefit means that the developers of disease management programmes for coronary heart disease should include rigorous evaluations of long term outcomes to confirm that the intended benefits have been attained.
We acknowledge the help of Dr N C Campbell (references 10 and 11), Dr R West (reference 22), and Dr M Naylor (references 12 and 26) in providing further details about their studies.
Contributors: FAMcA conceived and designed the study, collected and analysed the data, drafted the paper (and subsequent revisions), and is the guarantor. FMEL assisted with the design of the study, the collection of data, and critical revisions of the paper. KKT and PWA assisted with the design of the study and critical revisions of the paper.
Funding FAMcA is a population health investigator of the Alberta Heritage Foundation for Medical Research.
Competing interests PWA has consulted for Pfizer and received a research grant from Novartis in the past five years.